Halozyme Therapeutics Non-GAAP EPS of $1.60 beats by $0.08, revenue of $376.71M beats by $17.66M
Source: SeekingAlpha
2026-05-11 16:04:15 ET
More on Halozyme Therapeutics
- Halozyme Therapeutics: The Royalty Engine Is Becoming A Drug-Delivery Toll Road
- Halozyme Therapeutics, Inc. (HALO) Presents at The Citizens Life Sciences Conference 2026 Transcript
- Halozyme Therapeutics, Inc. (HALO) Presents at Leerink Global Healthcare Conference 2026 Transcript
- Argenx wins FDA nod to broaden Vyvgart label in myasthenia gravis
- Halozyme Therapeutics Q1 2026 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Halozyme Therapeutics Non-GAAP EPS of $1.60 beats by $0.08, revenue of $376.71M beats by $17.66M
Halozyme Therapeutics Inc.
NASDAQ: HALO
HALO Trading
1.16% G/L:
$70.39 Last:
67,756 Volume:
$70.61 Open:
HALO Latest News
May 11, 2026 04:01:00 pm
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
HALO Stock Data
$9,572,395,800
114,186,687
0.24%
276
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
